Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 21.67% is 54% above its 5-year average of 14.05%, near the high end of its 5-year range (-2.95%–23.53%).
1.04% below its 12-month average of 21.90%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 22.90%.
EBITDA MARGIN
21.67%
EBITDA MARGIN AVG TTM
21.90%
EBITDA MARGIN AVG 3Y
20.66%
EBITDA MARGIN AVG 5Y
14.05%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1.04%
CURRENT VS 3Y AVG
+4.91%
CURRENT VS 5Y AVG
+54.28%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
GoodRx Holdings, Inc.
Market Cap
$1.15B
EBITDA Margin
21.67%
TTM Avg
21.90%
3Y Avg
20.66%
5Y Avg
14.05%
Market Cap
$1.15B
EBITDA Margin
-234.91%
TTM Avg
-168.66%
3Y Avg
-182.22%
5Y Avg
-232.17%
Market Cap
$1.13B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.13B
EBITDA Margin
28.28%
TTM Avg
32.08%
3Y Avg
32.10%
5Y Avg
26.80%
Market Cap
$1.13B
EBITDA Margin
21.12%
TTM Avg
16.04%
3Y Avg
11.58%
5Y Avg
9.26%
Market Cap
$1.13B
EBITDA Margin
-20.99%
TTM Avg
-14.27%
3Y Avg
-11.56%
5Y Avg
-5.13%
Market Cap
$1.10B
EBITDA Margin
-15.54%
TTM Avg
-15.54%
3Y Avg
-2.35%
5Y Avg
5.20%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GoodRx Holdings, Inc. (GDRX) | $1.15B | 21.67% | 21.90% | 20.66% | 14.05% |
| Nektar Therapeutics (NKTR)vs › | $1.15B | -234.91% | -168.66% | -182.22% | -232.17% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.13B | N/A | N/A | N/A | N/A |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.13B | 28.28% | 32.08% | 32.10% | 26.80% |
| Harrow Health, Inc. (HROW)vs › | $1.13B | 21.12% | 16.04% | 11.58% | 9.26% |
| OPKO Health, Inc. (OPK)vs › | $1.13B | -20.99% | -14.27% | -11.56% | -5.13% |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.17B | N/A | N/A | N/A | N/A |
| STAAR Surgical Company (STAA)vs › | $1.10B | -15.54% | -15.54% | -2.35% | 5.20% |
| Replimune Group, Inc. (REPL)vs › | $1.10B | N/A | N/A | N/A | N/A |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | N/A | N/A | N/A | N/A |
Gross Margin
88.0%
EBITDA Margin
21.7%
Operating Margin
10.3%
Net Margin
2.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 22.90% |
| 2026-03-31 | 21.31% |
| 2025-12-31 | 23.53% |
| 2025-09-30 | 18.39% |
| 2025-06-30 | 23.36% |
| 2025-03-31 | 21.82% |
| 2024-12-31 | 18.77% |
| 2024-09-30 | 19.43% |
| 2024-06-30 | 18.37% |
| 2024-03-31 | 11.79% |
| 2023-12-31 | 12.88% |
| 2023-09-30 | -2.95% |
| 2023-06-30 | 18.67% |
| 2023-03-31 | 14.26% |
| 2022-12-31 | 9.38% |
| 2022-09-30 | -0.94% |
| 2022-06-30 | 4.83% |
| 2022-03-31 | 15.31% |
| 2021-12-31 | 10.51% |
| 2021-09-30 | 8.80% |
| 2021-06-30 | 4.54% |
| 2021-03-31 | 0.23% |
| 2020-12-31 | -192.15% |
| 2020-09-30 | -40.24% |
| 2020-06-30 | 37.52% |
| 2020-03-31 | 35.99% |
| 2019-12-31 | 35.30% |
| 2019-09-30 | 40.74% |
| 2019-06-30 | 44.73% |
| 2019-03-31 | 42.02% |
